All In Biotech

Drug Trial Radar · NCT06648850

Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,120

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

Mar 19, 2027

Study completion Apr 26, 2027

Sponsor

Lead sponsor
Applied Biology, Inc.Industry
Sponsor type
Industry
Collaborators
Follea International Limited; Daniel Alain, Inc.
First posted
Oct 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth

Conditions

  • Telogen Effluvium
  • Female Pattern Hair Loss
  • Female Pattern Hair Loss, Androgenic Alopecia
  • Male Pattern Baldness
  • Androgenetic Alopecia
  • Androgenetic Alopecia (AGA)

Interventions

  • DA-001Drug

    Phenylephrine 2.5% Topical + TAAR Agonist (GRAS) Topical Solution

  • PlaceboOther

    Placebo Topical Solution

  • PhenylephrineDrug

    Phenylephrine 2.5% Topical

  • DA-001 Topical + DA-005 Oral (HIF-1α supplement)Other

    DA-001 Topical (Phenylephrine 2.5% Topical + TAAR agonist tyramine) + DA-005 Oral (HIF-1α supplement)

  • DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)Other

    Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)

  • Phenylephrine Topical 0.25% + Intact Pro TopicalDrug

    Phenylephrine 0.25% + Intact Pro (50% stronger)

  • Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement)Other

    Phenylephrine 0.25% + Intact Pro (50% stronger) + DA-005 Oral (HIF-1α supplement)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Hair SheddingTime frame: Minutes [0,5]

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.